TORONTO, Jan. 21, 2019 /CNW/ - Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com ("Liberty" or the "Company"), a provider of high quality cannabis, is pleased to announce the appointment of Ian McKinnon and John Hick to its Board of Directors. Mr. McKinnon will assume the role of Chairman of the Board. Vic Neufeld and John Cervini, who had previously announced they would resign from the Company's Board of Directors as of January 31, 2019, accelerated their resignations to be effective January 18, 2019, and Mr. Hick's and Mr. McKinnon's appointments are both effective as of such date.
"Following an extensive search for qualified, independent board candidates, we are very excited to welcome Ian and John to our Board," said George Scorsis, CEO of Liberty Health Sciences. "These additions underscore our commitment to strengthening our corporate governance by enhancing the independence at the Board level. We look forward to working with Ian and John and believe they possess the necessary skills and expertise to support the next stage of Liberty's growth, which includes the anticipated completion of our state-of-the-art Liberty 360 processing and production facility, the significant expansion of our workforce and the planned opening of more than 30 dispensaries throughout Florida, Ohio and potentially other markets in the U.S. throughout 2019."
Mr. Hick is a seasoned leader and independent corporate director, who has been at the helm of several different companies and has his own private consulting company. Previously, Mr. Hick was on the board of First Uranium and served as Lead Independent Director from May 2010 to September 2012 during its restructuring. He was President, Chief Executive Officer and a director of Medoro Resources Ltd. from October 2009 to September 2010. Prior thereto, he held senior management and/or director positions with a number of publicly listed companies, mainly in the mining sector. Currently, Mr. Hick serves as a director of Diamond Estates Wines & Spirits Ltd., Eurotin Inc., LSC Lithium Corp., Mako Mining Corp., Quebec Precious Metals Corp., Samco Gold Ltd., and Sphinx Resources Ltd. Mr. Hick holds a BA from the University of Toronto, an LLB from the University of Ottawa and was called to the Bar of Ontario in 1978.
Mr. McKinnon is an experienced CEO and independent board member with more than 30 years of experience leading international technology companies. Between 1995 and 2007, Mr. McKinnon was President, Chief Executive Officer and a member of the Board of Directors of Promis Systems Corporation Ltd. and Certicom Corp. Previously, he was a member of the Board of Directors of TSX listed Constellation Software Inc., TSX/Nasdaq listed Smart Technologies and Allstream, in addition to Adeptron and Vendtek Systems. He currently sits on the boards of TSX/Nasdaq listed Quarterhill and is chair of privately owned Messagepoint. Mr. McKinnon holds an Honors B.A. from McMaster University and attended the INSEAD Advanced Management Program.
About Liberty Health Sciences Inc.
Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale and beyond. Liberty's measured approach to expansion opportunities maximizes returns to shareholders, while keeping consumers' well-being at the forefront of what we do. For more information, please visit: www.libertyhealthsciences.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
SOURCE Liberty Health Sciences Inc.
For further information: Media Contacts: Dwain Schenck, 203-223-5230, firstname.lastname@example.org; Stephanie Kubacki, Vice-President, Marketing, 415-830-7337, email@example.com